Cell Therapy News Volume 23.38 | Nov 7 2022

    0
    23








    2022-11-07 | CTN 23.38


    Cell Therapy News by STEMCELL Technologies
    Vol. 23.38 – 7 November, 2022
    TOP STORY

    Interventions and Outcomes of Multiple Myeloma Patients Receiving Salvage Treatment after BCMA-Directed CAR T Therapy

    Researchers analyzed the salvage treatments and outcomes of 79 patients with multiple myeloma from two academic institutions who had progression of disease after treatment with B cell maturation antigen-directed CAR T.
    [Blood]

    Abstract
    World Oncology Cell Therapy Congress 2023
    PUBLICATIONSRanked by the impact factor of the journal

    Tissue-Engineered Grafts Exploit Axon-Facilitated Axon Regeneration and Pathway Protection to Enable Recovery after 5-cm Nerve Defects in Pigs

    Investigators developped tissue-engineered nerve grafts to simultaneously “bridge” missing nerve segments and “babysit” regenerative capacity by providing living axons to guide host axons and maintain the distal pathway.
    [Science Advances]

    Full Article

    Effect of Granulocyte Colony-Stimulating Factor on Toxicities after CAR T Cell Therapy for Lymphoma and Myeloma

    To investigate the impact of granulocyte colony-stimulating factor, the authors analyzed 197 patients treated with anti-CD19 CAR T for lymphoma and 47 patients treated with anti-B cell maturation antigen CAR T for multiple myeloma.
    [Blood Cancer Journal]

    Full Article

    Autologous Stem-Cell Transplantation as Consolidation of First-Line Chemotherapy in Patients with Peripheral T-cell Lymphoma: A Multicenter GELTAMO/FIL Study

    Investigators designed a multicenter, retrospective study with the main objective of comparing progression-free survival and overall survival of patients with peripheral T-cell lymphomas who underwent autologous stem cell transplantation in complete remission after first-line chemotherapy.
    [Haematologica]

    Full Article

    Co-Transplantation of Pancreatic Islets and Microvascular Fragments Effectively Restores Normoglycemia in Diabetic Mice

    Scientists co-transplanted 250 islets and 20,000 adipose tissue-derived microvascular fragments (MVF) from donor mice under the kidney capsule as well as 500 or 1000 islets with 40,000 MVF into the subcutaneous space of diabetic mice.
    [NPJ Regenerative Medicine]

    Full Article

    Intestinal Epithelial Stem Cell Transplants as a Novel Therapy for Cerebrovascular Stroke

    Researchers tested whether repairing the gut via intestinal epithelial stem cell transplants would also improve stroke recovery.
    [Brain, Behavior, and Immunity]

    Full Article

    A Novel Polymer-Conjugated Human IL-15 Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

    In vivo studies in lymphoma-bearing immunodeficient mice demonstrated enhanced antitumor efficacy of human CD19 CAR-T. In contrast to mice treated with CAR-T alone, those that received CAR-T and NKTR-255 had markedly higher CAR-T counts in blood and marrow.
    [Blood Advances]

    Abstract

    T Cell Counts in Peripheral Blood at Leukapheresis Predict Responses to Subsequent CAR-T Cell Therapy

    Scientists evaluated the clinical impact of CD3+ cell count in peripheral blood at leukapheresis on clinical outcomes of CAR-T cell therapy.
    [Scientific Reports]

    Full Article

    Attenuation of Experimental Osteoarthritis with Human Adipose-Derived Mesenchymal Stem Cell Therapy: Inhibition of the Pyroptosis in Chondrocytes

    Human adipose-derived mesenchymal stem cells were administrated in the articular cavity by injection in vivo and co-cultured with chondrocytes using transwell in vitro.
    [Inflammation Research]

    Abstract
    Win an award toward an upcoming cell or gene therapy conference
    REVIEWS

    Engineered and Banked iPSCs for Advanced NK and T Cell Immunotherapies

    The authors highlight recent progress in induced pluripotent stem cells (iPSCs) editing and guided differentiation to develop natural killer (NK) and T cell products for immunotherapy.
    [Blood]

    Abstract

    The PO4-tential for Less Toxic CAR T-cell Therapies

    Scientists demonstrate an association between hypophosphatemia and CAR T cell-induced immune effector cell–associated neurotoxicity syndrome.
    [Cancer Immunology Research]

    Abstract
    INDUSTRY AND POLICY NEWS

    US Agency Seeks to Phase Out Animal Testing

    The US FDA has set out proposals for the New Alternative Methods Program that will focus on replacing, reducing and refining the use of laboratory animals through the adoption of cutting-edge alternative methods.
    [Nature News]

    Press Release

    Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T Cell Therapy Engager ALETA-001

    Aleta Biotherapeutics announced that the UK Medicines and Healthcare products Regulatory Agency has granted an Innovation Passport under the Innovative Licensing and Access Pathway for CAR T cell therapy Engager candidate ALETA-001 for the treatment of patients suffering from the B-cell malignancies.
    [Aleta BioTherapeutics]

    Press Release
    FEATURED EVENT

    Drug Delivery to the Brain: Challenges and Progress

    January 23 – 25, 2023
    Breckenridge, Colorado, United States

    > See All Events

    JOB OPPORTUNITIES

    University Professor – Transfusion Medicine

    University Medical Center of the Johannes Gutenberg University Mainz – Mainz, Germany

    Faculty Position – Regenerative Medicine

    University of Nebraska Medical Center – Omaha, Nebraska, United States

    Research Associate – Liver R&D

    Aspect Biosystems – Vancouver, British Columbia, Canada

    Postdoctoral Scientist – Cancer Regulators

    University of Texas Health Science Center at Houston – Houston, Texas, United States

    Postdoctoral Associate – Therapy-Resistance of Human Cancers

    Baylor College of Medicine – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter